Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer - PubMed (original) (raw)
Randomized Controlled Trial
. 2019 Jun 20;380(25):2395-2405.
doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.
Robert J Gray 1, Peter M Ravdin 1, Della F Makower 1, Kathleen I Pritchard 1, Kathy S Albain 1, Daniel F Hayes 1, Charles E Geyer Jr 1, Elizabeth C Dees 1, Matthew P Goetz 1, John A Olson Jr 1, Tracy Lively 1, Sunil S Badve 1, Thomas J Saphner 1, Lynne I Wagner 1, Timothy J Whelan 1, Matthew J Ellis 1, Soonmyung Paik 1, William C Wood 1, Maccon M Keane 1, Henry L Gomez Moreno 1, Pavan S Reddy 1, Timothy F Goggins 1, Ingrid A Mayer 1, Adam M Brufsky 1, Deborah L Toppmeyer 1, Virginia G Kaklamani 1, Jeffrey L Berenberg 1, Jeffrey Abrams 1, George W Sledge Jr 1
Affiliations
- PMID: 31157962
- PMCID: PMC6709671
- DOI: 10.1056/NEJMoa1904819
Randomized Controlled Trial
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A Sparano et al. N Engl J Med. 2019.
Abstract
Background: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.
Methods: We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, axillary node-negative breast cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger.
Results: The level of clinical risk was prognostic of distant recurrence in women with an intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low clinical risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus endocrine (chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in women with a high recurrence score (a score of 26 to 100), all of whom were assigned to chemoendocrine therapy (hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who were 50 years of age or younger who had received endocrine therapy alone, the estimated (±SE) rate of distant recurrence at 9 years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this age group, the estimated distant recurrence at 9 years exceeded 10% among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone (12.3±2.4%) and among those with a high recurrence score who received chemoendocrine therapy (15.2±3.3%).
Conclusions: Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
Copyright © 2019 Massachusetts Medical Society.
Figures
Figure 1.. Effect of Clinical Risk on Prognosis in the Entire Population and Stratified According to Age.
Hazard ratios and 95% confidence intervals (CIs) for a high versus low clinical risk of invasive disease recurrence, second primary cancer, or death and for distant recurrence (a hazard ratio of >1 indicates a higher event rate with high clinical risk) are shown. There were no distant recurrences among 64 patients in the subgroup who had a high clinical risk and a low recurrence score. CIs have not been adjusted for multiple comparisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the size of the subgroup; the horizontal lines represent the 95% CI.
Figure 2.. Effect of Clinical Risk on Prediction of Chemotherapy Benefit.
Panel A shows the effect of clinical risk on prediction of chemotherapy benefit in 6496 women with a recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly assigned to endocrine therapy or chemotherapy plus endocrine (chemoendocrine) therapy, and stratified according to age. A total of 4353 women were older than 50 years of age, and 2143 women were 50 years of age or younger. Panel B shows the effect of clinical risk on prediction of chemotherapy benefit in 2143 women who were 50 years of age or younger and had a recurrence score of 11 to 25. Estimated hazard ratios are shown for treatment (endocrine vs. chemoendocrine therapy) and 95% CIs for invasive disease–free survival and distant recurrence (a hazard ratio >1 indicates that chemoendocrine therapy is better). CIs have not been adjusted for multiple comparisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the size of the subgroup; the horizontal lines represent the 95% CI.
Figure 3.. Effect of Age and Menopausal Status on Chemotherapy Benefit.
Shown is the effect of age and menopausal status on chemotherapy benefit in 4338 women who had a recurrence score of 16 to 25 and were randomly assigned to endocrine therapy or chemoendocrine therapy. Estimated treatment hazard ratios (endocrine vs. chemoendocrine therapy) and 95% CIs for rates of distant recurrence at 9 years are shown (a hazard ratio >1 indicates that chemoendocrine therapy is better). Menopause was defined as an age of 60 years or older; an age of 45 to 59 years with spontaneous cessation of menses for at least 12 months before registration; an age of 45 to 59 years with cessation of menses for less than 12 months before registration and a follicle-stimulating hormone (FSH) level in the postmenopausal range (or >34.4 IU per liter if the institutional range was not available); prior bilateral oophorectomy; or age younger than 60 years with prior hysterectomy without bilateral oophorectomy and an FSH level in the postmenopausal range (or >34.4 IU per liter if the institutional range was not available). CIs have not been adjusted for multiple comparisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the size of the subgroup; the horizontal lines represent the 95% CI.
Comment in
- Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer.
Schvartsman G, Kaliks RA. Schvartsman G, et al. N Engl J Med. 2019 Sep 26;381(13):1289-1291. doi: 10.1056/NEJMc1909693. N Engl J Med. 2019. PMID: 31553844 No abstract available. - Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer.
Giorgi Rossi P, Lebeau A, Schünemann HJ; Multigene Test PICO (Population, Intervention, Comparison, Outcome) Responsible Unit of the Guidelines Development Group, European Commission Initiative on Breast Cancer. Giorgi Rossi P, et al. N Engl J Med. 2019 Sep 26;381(13):1289-1290. doi: 10.1056/NEJMc1909693. N Engl J Med. 2019. PMID: 31553845 No abstract available.
Similar articles
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3. N Engl J Med. 2018. PMID: 29860917 Free PMC article. Clinical Trial. - 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial. - Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Sparano JA, et al. N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27. N Engl J Med. 2015. PMID: 26412349 Free PMC article. Clinical Trial. - [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L, Blanc-Vincent MP, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Zafrani B, Dilhuydy JM. Mauriac L, et al. Bull Cancer. 2000 Jun;87(6):469-90. Bull Cancer. 2000. PMID: 10903789 Review. French. - Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M, Munzone E. Colleoni M, et al. Drugs. 2015 Aug;75(12):1311-21. doi: 10.1007/s40265-015-0433-7. Drugs. 2015. PMID: 26177891 Review.
Cited by
- Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study.
Guerrero-Zotano Á, Pérez-García JM, Ruiz-Borrego M, Bermejo B, Gil-Gil M, de la Haba J, Alba Conejo E, Quiroga V, Carañana V, Urruticoechea A, Morales S, Bellet M, Antón A, Fernández-Abad M, Sánchez-Rovira P, Calabuig L, Pérez-Escuredo J, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Guerrero-Zotano Á, et al. ESMO Open. 2024 Sep 30;9(10):103733. doi: 10.1016/j.esmoop.2024.103733. Online ahead of print. ESMO Open. 2024. PMID: 39353215 Free PMC article. - Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer.
Freeman JQ, Shubeck SP, Chen N, Yarlagadda SR, Nanda R, Huo D, Howard FM. Freeman JQ, et al. Ann Surg Oncol. 2024 Sep 9. doi: 10.1245/s10434-024-16160-5. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39251516 - Prediction of disease-free survival using strain elastography and diffuse optical tomography in patients with T1 breast cancer: a 10-year follow-up study.
Zhang J, Sun H, Gao S, Kang Y, Shang C. Zhang J, et al. BMC Cancer. 2024 Aug 27;24(1):1057. doi: 10.1186/s12885-024-12844-z. BMC Cancer. 2024. PMID: 39192199 Free PMC article. - Efficacy of FERscore in predicting sensitivity to ferroptosis inducers in breast cancer.
Hu K, Qiu J, Hu Y, Wang Y, Yu C, Wu Y. Hu K, et al. NPJ Breast Cancer. 2024 Aug 20;10(1):74. doi: 10.1038/s41523-024-00685-9. NPJ Breast Cancer. 2024. PMID: 39164282 Free PMC article. - Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images.
Sharma A, Lövgren SK, Eriksson KL, Wang Y, Robertson S, Hartman J, Rantalainen M. Sharma A, et al. Breast Cancer Res. 2024 Aug 14;26(1):123. doi: 10.1186/s13058-024-01879-6. Breast Cancer Res. 2024. PMID: 39143539 Free PMC article.
References
- Early Breast Cancer Trialists’ Collab-orative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717. - PubMed
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26. - PubMed
- Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34. - PubMed
- Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55–65. - PMC - PubMed
- Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA180868/CA/NCI NIH HHS/United States
- U10 CA180801/CA/NCI NIH HHS/United States
- UG1 CA190140/CA/NCI NIH HHS/United States
- U24 CA196172/CA/NCI NIH HHS/United States
- U10 CA180795/CA/NCI NIH HHS/United States
- UG1 CA233160/CA/NCI NIH HHS/United States
- UG1 CA233373/CA/NCI NIH HHS/United States
- U10 CA180820/CA/NCI NIH HHS/United States
- U10 CA180888/CA/NCI NIH HHS/United States
- U10 CA180822/CA/NCI NIH HHS/United States
- UG1 CA189804/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- UG1 CA189859/CA/NCI NIH HHS/United States
- UG1 CA189869/CA/NCI NIH HHS/United States
- U10 CA180821/CA/NCI NIH HHS/United States
- P30 CA016086/CA/NCI NIH HHS/United States
- U10 CA180857/CA/NCI NIH HHS/United States
- U10 CA180847/CA/NCI NIH HHS/United States
- U10 CA180863/CA/NCI NIH HHS/United States
- U10 CA180790/CA/NCI NIH HHS/United States
- UG1 CA233247/CA/NCI NIH HHS/United States
- UG1 CA189808/CA/NCI NIH HHS/United States
- U10 CA180794/CA/NCI NIH HHS/United States
- UG1 CA233253/CA/NCI NIH HHS/United States
- U10 CA180799/CA/NCI NIH HHS/United States
- U10 CA180838/CA/NCI NIH HHS/United States
- U10 CA180816/CA/NCI NIH HHS/United States
- U10 CA180844/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials